Enliven Therapeutics, Inc. (ELVN) Stock Score, Valuation & Financial Research

Enliven Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ELVN

Enliven Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 42.39. These figures are a research snapshot, not a buy or sell recommendation.

What Enliven Therapeutics, Inc. does

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Enliven Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research, discovery, and development of small molecule therapeutics, relying on capital raises and financial reserves to fund ongoing clinical trials and operational expenses.

Products and services

  • The company is developing a pipeline of small molecule therapeutics, primarily focusing on ELVN-001 for the treatment of chronic myeloid leukemia (CML).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party vendors for clinical trial management, data collection, and the manufacturing of drug candidates for clinical use. Source

Competitors and product-market comparisons

  • Novartis — Competes in the oncology market, specifically regarding treatments for chronic myeloid leukemia. Source
  • Bristol Myers Squibb — Competes in the oncology market, specifically regarding treatments for chronic myeloid leukemia. Source

Business strengths to evaluate

  • Strong balance sheet with significant cash and cash equivalents to fund operations into 2029 Source
  • Advancement of lead candidate ELVN-001 into pivotal clinical trials Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses for the foreseeable future Source
  • Dependence on the success of a limited number of clinical-stage product candidates Source
  • Reliance on third-party manufacturers and clinical research organizations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ELVN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 42.39
Market capitalization:
3.03B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -105.93M
Free cash flow:
USD -70.46M
Cash:
USD 135.51M
Total debt:
USD 1.51M
EPS:
USD -1.64

What stands out

  • Free cash flow is USD -70.46M, negative for the stored period.
  • The balance sheet shows USD 135.51M of cash versus USD 1.51M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 134M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ELVN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ELVN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ELVN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ELVN to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ELVN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ELVN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.